Harding S P, Porter S M
St. Paul's Eye Hospital, Liverpool, UK.
Curr Eye Res. 1991;10 Suppl:177-82. doi: 10.3109/02713689109020376.
46 patients with acute herpes zoster ophthalmicus of less than 72 hours duration were recruited into a placebo controlled trial to assess the efficacy of oral acyclovir, 800 mg 5 times daily, in preventing or modifying ocular complications and pain. Fewer acyclovir recipients developed intraocular complications and these were less severe but neither difference was statistically significant. However, active ocular disease was significantly less common in the acyclovir group (p = 0.01) at 6 months. Pain was significantly less severe in the acyclovir group between 2 and 6 months. The proportion of patients with pain scores greater than 0 was significantly lower in the acyclovir group between 2 and 3 months. Oral acyclovir appears to modify the disease process in herpes zoster ophthalmicus, to reduce the severity and incidence of postherpetic pain and especially to protect against long-term ocular complications.
46例病程小于72小时的急性眼带状疱疹患者被纳入一项安慰剂对照试验，以评估口服阿昔洛韦（每日5次，每次800毫克）预防或改善眼部并发症及疼痛的疗效。接受阿昔洛韦治疗的患者发生眼内并发症的较少，且病情较轻，但两者差异均无统计学意义。然而，在6个月时，阿昔洛韦组活动性眼部疾病明显较少见（p = 0.01）。在2至6个月期间，阿昔洛韦组的疼痛明显较轻。在2至3个月期间，阿昔洛韦组疼痛评分大于0的患者比例明显较低。口服阿昔洛韦似乎可改变眼带状疱疹的疾病进程，减轻带状疱疹后神经痛的严重程度和发生率，尤其是预防长期眼部并发症。
